Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hinge Health Inc. Class A Common Stock (HNGE) vs ING Groep NV (ING) Price & Performance

Hinge Health Inc. Class A Common StockTrade
ING Groep NVTrade

Price performance (Past 24H)

Key statistics

Hinge Health Inc. Class A Common Stock vs ING Groep NV — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while ING Groep NV trades at $33.08 (market cap $95.72B). The key difference: ING Groep NV is far larger — about 11.3× Hinge Health Inc. Class A Common Stock's market cap, and ING Groep NV pays a 3.95% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and ING Groep NV for 94 Days on average.

HNGEING
Market Cap
$8.47B$95.72B
Volume
1,624,5262,335,394
Sector
HealthFinancials
52-Week High
$105.14$37.27
52-Week Low
$31.17$23.66
Typical Hold Time
0 Days94 Days
Enterprise Value
$8.09B$235.88B
Dividend Yield
—3.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hinge Health Inc. Class A Common Stock

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

ING Groep NV

ING trades at $33.63, up 0.72% today, with a bearish technical signal but strong fundamentals including a 28.34% net income margin and consistent earnings beats. Recent news highlights management's raised ROE target above 16% for 2027, driven by revenue growth and AI initiatives. Cash flow trends show volatile net outflows, with 2025 net cash flow at -$14.92 billion.

The outlook is mixed: analyst consensus is bullish with 65% buy ratings, but technical indicators and cash flow volatility pose risks. Upside potential hinges on execution of growth strategies and cost discipline, while regulatory scrutiny and macroeconomic pressures remain key watchpoints for investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HNGE
100% Buy0% Sell
Avg holding period · 0 Days
ING
100% Buy0% Sell
Avg holding period · 94 Days

About Hinge Health Inc. Class A Common Stock

Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.

Read more on HNGE →

About ING Groep NV

The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.

Read more on ING →